Skip to main content
PMC home page
Elsevier - PMC COVID-19 Collection logoLink to Elsevier - PMC COVID-19 Collection
. 2004 May 14;93(12):845–850. doi: 10.1016/S0954-6111(99)90048-3

Infection in acute exacerbations of chronic bronchitis: a clinical perspective

RC Read 1,∗
PMCID: PMC7173073  PMID: 10653044

Abstract

Acute exacerbations of chronic bronchitis (AECB) is an important cause of death and morbidity in developed countries and also has significant economic impact. The disease is characterized by increased dyspnoea, sputum volume and sputum purulence; the most commonly associated pathogens are Haemophilus influenzae, Streptococcus pneumoniae and Moraxella catarrhalis. H. influenzae and S. pneumoniae express virulence determinants that directly and indirectly impair mucociliary clearance and incite other consequences that are permissive to microbial persistence.

Regarding the use of antibiotics, there is currently a lack of large-scale clinical trials that are sufficiently powerful to provide good evidence-based information. Nonetheless, antimicrobial chemotherapy has repeatedly been shown to confer benefit in patients with moderately severe features of AECB. Simple clinical criteria can be used to identify patients in whom there is a higher likelihood of treatment failure or mortality during AECB. These include significant cardiopulmonary co-morbidity, frequent exacerbations, advanced decline in lung function, malnutrition or other generalized debility, advanced age (> 70 years) and concurrent treatment with corticosteroids. In such patients, an aggressive antimicrobial approach to AECB may be warranted in order to prevent clinical failure or representation. From a clinical perspective, appropriate drugs include those that are stable to β-lactamases, are bactericidal against causative pathogens, penetrate diseased lung tissue in high concentrations and have a good safety profile.

References

  • 1.US Bureau of the Census . 3rd ed. US Bureau of the Census; Washington DC: 1991. Statistical Abstract of the United States. [Google Scholar]
  • 2.Thurlbeck WM. Pathophysiology of Chronic Obstructive Pulmonary Disease. Clin Chest Med. 1990;11:389–403. [PubMed] [Google Scholar]
  • 3.Meier CF, Jick SS, Derby LE, Vasilakis C, Jick H. Acute Respiratory Tract Infections and Risk of First Time Acute Myocardial Infarction. Lancet. 1998;351:1467–1471. doi: 10.1016/s0140-6736(97)11084-4. [DOI] [PubMed] [Google Scholar]
  • 4.Read RC, Wilson R, Rutman A, Geoffrey PK, Cole PJ. Interaction of non-typable Haemophilus influenzae of human respiratory mucosa in vitro. J Infect Dis. 1991;163:549–558. doi: 10.1093/infdis/163.3.549. [DOI] [PubMed] [Google Scholar]
  • 5.May JR. The bacteriology of chronic bronchitis. Lancet. 1953;2:534–537. doi: 10.1016/s0140-6736(53)90274-8. [DOI] [PubMed] [Google Scholar]
  • 6.Bjerkestrand G, Digranes A, Schreiner A. Bacteriological findings in trans-tracheal aspirates from patients with chronic bronchitis and bronchiectasis. Scand J Resp Dis. 1975;56:201–207. [PubMed] [Google Scholar]
  • 7.Monso E, Ruiz J, Roselle A, Manterolo J, Fiz J, Morera J, Ausina V. Bacterial infection in chronic obstructive pulmonary disease. Am J Resp Crit Care Med. 1995;152:120–131. doi: 10.1164/ajrccm.152.4.7551388. [DOI] [PubMed] [Google Scholar]
  • 8.Soler N, Torres A, Ewig S, Gonzales J, Celis R. Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease requiring mechanical ventilation. Am J Resp Crit Care Med. 1998;157:1498–1505. doi: 10.1164/ajrccm.157.5.9711044. [DOI] [PubMed] [Google Scholar]
  • 9.Groenveld K, Alphen LV, Eijk PP. Endogenous reinfections by Haemophilus influenzae in patients with chronic obstructive pulmonary disease: the effect of antibiotic treatment on persistence. J Infect Dis. 1990;161:512–517. doi: 10.1093/infdis/161.3.512. [DOI] [PubMed] [Google Scholar]
  • 10.Read RC, Finch RG. Bacterial infections of the respiratory tract. In: Sussman M., Baylow G.L., editors. 2nd ed. Vol. 3. Arnold; London: 1998. pp. 319–347. (Topley and Wilson's Systemic Microbiology). [Google Scholar]
  • 11.Ball P. Epidemiology and treatment of chronic bronchitis and its exacerbations. Chest. 1995;108:43S–52S. doi: 10.1378/chest.108.2_Supplement.43S. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Fagon J-Y, Chastre J, Trouille J-L, Domart Y, Dombret M-C, Bornet M, Gibert C. Characterisation of distal bronchial microflora during acute exacerbation of chronic bronchitis. Am Rev Resp Dis. 1990;142:1004–1008. doi: 10.1164/ajrccm/142.5.1004. [DOI] [PubMed] [Google Scholar]
  • 13.Gump DW, Phillips EA, Forsyth BR. Role of infection in chronic bronchitis. Am Rev Resp Dis. 1976;113:465–473. doi: 10.1164/arrd.1976.113.4.465. [DOI] [PubMed] [Google Scholar]
  • 14.Saint S, Bent S, Vittinghoff E, Grady D. Antibiotics in chronic obstructive pulmonary disease exacerbations. JAMA. 1995;273:957–960. [PubMed] [Google Scholar]
  • 15.Orn PH, Scherer K, Macdonald A, Moffatt ME. Randomized placebo-controlled trials of antibiotics for acute bronchitis: A critical review of the literature. J Fam Pract. 1993;36:507–512. [PubMed] [Google Scholar]
  • 16.Elmes PC, Fletchen CM, Dutton AAC. Prophylactic use of oxytetracycline for exacerbations of chronic bronchitis. Br Med J. 1957;2:1272–1275. doi: 10.1136/bmj.2.5056.1272. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Berry DG, Fry J, Hindley CP. Exacerbations of chronic bronchitis treatment with oxytetracycline. Lancet. 1960;1:137–139. doi: 10.1016/s0140-6736(60)90056-8. [DOI] [PubMed] [Google Scholar]
  • 18.Fear EC, Edwards G. Antibiotic regimes in chronic bronchitis. Br L Dis Chest. 1962;56:153–162. doi: 10.1016/s0007-0971(62)80012-6. [DOI] [PubMed] [Google Scholar]
  • 19.Elmes PC, King TKC, Langlands JHM. Value of ampicillin in the hospital treatment of exacerbations of chronic bronchitis. Br Med J. 1965;2:904–908. doi: 10.1136/bmj.2.5467.904. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Petersen ES, Esmann V, Honcke P, Munknes C. A controlled study of the effect of treatment of chronic bronchitis: an evaluation using pulmonary function tests. Acta Med Scand. 1967;182:293–301. doi: 10.1111/j.0954-6820.1967.tb11527.x. [DOI] [PubMed] [Google Scholar]
  • 21.Pines A, Raafat H, Greenfield JSB, Linsell WD, Solari ME. Antibiotic regimens in moderately ill Patients with purulent exacerbations of chronic bronchitis. Br J Dis Chest. 1972;66:107–115. [PubMed] [Google Scholar]
  • 22.Nicotra MB, Rivera M, Awe RJ. Antibiotic therapy of acute exacerbations of chronic bronchitis. Ann Intern Med. 1982;97:18–21. doi: 10.7326/0003-4819-97-1-18. [DOI] [PubMed] [Google Scholar]
  • 23.Anthonisen NR, Manfreda J, Warren CPW, Hershfield ES, Harding GKM, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 1987;106:196–204. doi: 10.7326/0003-4819-106-2-196. [DOI] [PubMed] [Google Scholar]
  • 24.Jorgensen AF, Coolidge J, Pedersen PA. Amoxicillin in treatment of acute uncomplicated exacerbations of chronic bronchitis. Scand J Prim Health Care. 1992;10:7–11. doi: 10.3109/02813439209014027. [DOI] [PubMed] [Google Scholar]
  • 25.Dorca J, Torres A. Lower respiratory tract infections in the community: towards a more rational approach. Eur Resp J. 1996;9:1588–1589. doi: 10.1183/09031936.96.09081588. [DOI] [PubMed] [Google Scholar]
  • 26.Siafakas NM. On behalf of the ERS. Optimal assessment in management of chronic obstructive pulmonary disease (COPD)Eur Resp J. 1995;8:1398–1420. doi: 10.1183/09031936.95.08081398. [DOI] [PubMed] [Google Scholar]
  • 27.American Thoracic Society Am J Resp Med Crit Care. 1995;152:77S–120S. doi: 10.1164/ajrccm.152.3.7663792. [DOI] [PubMed] [Google Scholar]
  • 28.The COPD Guidelines Group of the Standards of Care Committee of the BTS BTS Guidelines for the Management of Chronic Obstructive Pulmonary Disease. Management of acute exacerbations of COPDThorax. 1997;52(Suppl 5):S16–S21. [PMC free article] [PubMed] [Google Scholar]
  • 29.Felmingham D, Robbins MI, Tesfaslasie Y, Harding I, Shrimpton S, Grüneberg RN. Antimicrobial susceptibility of community-acquired lower respiratory tract bacterial pathogens isolated in the U.K. during the 1995–1996 cold season. J Antimicrob Chemother. 1998;41:411–415. doi: 10.1093/jac/41.3.411. [DOI] [PubMed] [Google Scholar]
  • 30.Retsema J, Girard A, Schelkley W. Spectrum and mode of action of azithromycin, a new 15-membered ring macrolide with improved potency against Gramnegative organisms. Antimicrob Agents Chemother. 1987;31:1939–1947. doi: 10.1128/aac.31.12.1939. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Amyes SGB, Gemmell CG. Antibiotic resistance. J Med Microbiol. 1997;46:436–470. [Google Scholar]
  • 32.Pallares L, Linares J, Vadillo M, Cabellos C, Manresa F, Viladrich BF. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Eng J Med. 1995;333:474–480. doi: 10.1056/NEJM199508243330802. [DOI] [PubMed] [Google Scholar]
  • 33.Friedland IR, McCracken GH. Management of infections caused by antibiotic resistant Streptococcus pneumoniae. N Eng J Med. 1994;331:377–380. doi: 10.1056/NEJM199408113310607. [DOI] [PubMed] [Google Scholar]
  • 34.Guillemot D, Carbon C, Balkau B, Geslin P, Lecoeur H. Low dosage and long treatment duration of β-lactam. JAMA. 1998;279:365–370. doi: 10.1001/jama.279.5.365. [DOI] [PubMed] [Google Scholar]
  • 35.Gonzales R, Sande M. What will it take to stop physicians from prescribing antibiotics in acute bronchitis? Lancet. 1995;345:665–666. doi: 10.1016/s0140-6736(95)90861-7. [DOI] [PubMed] [Google Scholar]
  • 36.Fahey T, Stocks N, Thomas T. Quantitative and systematic review of randomised control trials comparing antibiotic with placebo for acute cough in adults. Brit Med J. 1998;316:906–910. doi: 10.1136/bmj.316.7135.906. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Anthonisen NR, Wright EC, Hodgkin IE. Prognosis in chronic obstructive pulmonary disease. Am Rev Resp Dis. 1986;133:14–20. doi: 10.1164/arrd.1986.133.1.14. [DOI] [PubMed] [Google Scholar]
  • 38.Reid DD, Fairbaim AS. The natural history of chronic bronchitis. Lancet. 1958;2:1147–1152. doi: 10.1016/s0140-6736(58)91950-0. [DOI] [PubMed] [Google Scholar]
  • 39.Strom K. Survival of patients with chronic obstructive pulmonary disease receiving longterm domicillary oxygen therapy. Am Rev Resp Dis. 1993;147:585–591. doi: 10.1164/ajrccm/147.3.585. [DOI] [PubMed] [Google Scholar]
  • 40.Seneff MG, Wagner DP, Wagner RP, Zimmerman JE, Knaus WA. Hospital and one-year's survival of patients admitted to intensive care units with acute exacerbations of chronic obstructive pulmonary disease. JAMA. 1995;274:1852–1857. [PubMed] [Google Scholar]
  • 41.Prescott E, Lange P, Vestbo J. Chronic mucus hypersecretion in COPD and death from pulmonary infection. Eur Resp J. 1995;8:1333–1338. doi: 10.1183/09031936.95.08081333. [DOI] [PubMed] [Google Scholar]
  • 42.Ball P, Harris JM, Lowson D. Acute infective exacerbations of chronic bronchitis. Q J Med. 1995;88:61–68. [PubMed] [Google Scholar]
  • 43.Staley H, McDade HP, Poes D. Is an objective assessment of antibiotic therapy in exacerbations of chronic bronchitis possible? J Antimicrob Chemother. 1993;31:193–197. doi: 10.1093/jac/31.2.193. [DOI] [PubMed] [Google Scholar]

Articles from Respiratory Medicine are provided here courtesy of Elsevier

RESOURCES